Boehringer In­gel­heim taps Sino Bio­pharm as Chi­nese part­ner for its emerg­ing can­cer pipeline

As Boehringer In­gel­heim gears up for sev­er­al po­ten­tial can­cer drug launch­es over the next few years, it is team­ing up with an ex­pe­ri­enced part­ner to de­vel­op and com­mer­cial­ize those drugs in Chi­na.

The new al­liance with Sino Bio­pharm cov­ers mul­ti­ple Boehringer clin­i­cal-stage pro­grams, in­clud­ing brigi­madlin, an MDM2 in­hibitor act­ing on the p53 path­way; zonger­tinib, a small mol­e­cule HER2 ty­ro­sine ki­nase in­hibitor; and BI 764532, a DLL3/CD3 T cell en­gager.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.